A Phase I Study of Deferoxamine in People with Leptomeningeal Metastasis


Full Title

A Phase 1a/1b Trial of Intrathecal Deferoxamine for Leptomeningeal Metastases


Cancer that has spread from a solid tumor to the membranes lining the brain and spinal cord (leptomeninges) is called “leptomeningeal metastasis.” Cerebrospinal fluid (CSF) is located between the leptomeninges, in a place called the “intrathecal space.” Cancer cells within the CSF rely on iron for growth and survival. Researchers think that the study drug, deferoxamine (DFO), may be an effective treatment for leptomeningeal metastases because it helps remove iron from the body (including the CSF).

The purpose of this study is to find the highest dose of DFO that can be given safely in people with leptomeningeal metastases. Participants will receive DFO intrathecally (directly into the CSF) through a small plastic tube called an Ommaya reservoir.

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have leptomeningeal metastases from a solid tumor.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Adrienne Boire at 646-888-3786.




Phase I (phase 1)

Disease Status

Newly Diagnosed & Relapsed/Refractory



ClinicalTrials.gov ID